Literature DB >> 9790765

EDG6, a novel G-protein-coupled receptor related to receptors for bioactive lysophospholipids, is specifically expressed in lymphoid tissue.

M H Gräler1, G Bernhardt, M Lipp.   

Abstract

EDG receptors constitute a novel subfamily of G-protein-coupled receptors displaying a heterogeneous expression pattern. It was shown recently that the four members of this family thus far identified can bind lysophospholipids or lysosphingolipids as ligands. Here we report the identification and characterization of EDG6, a novel member of the EDG receptor family, isolated from in vitro differentiated human and murine dendritic cells. EDG6 is specifically expressed in fetal and adult lymphoid and hematopoietic tissue as well as in lung. The expression pattern of edg6 is strongly conserved in human and mouse. The human edg6 gene was mapped to chromosome 19p13.3 at the D19S120 marker. Considering the lymphoid-specific expression pattern of edg6 and the strong identity to the phospholipid-binding EDG receptor family, we propose that EDG6 may also act as a receptor for a lipid-derived ligand. Because of the known mitogenic and chemotactic activity of bioactive lipids, we believe that EDG6 may play an essential role in lymphocyte cell signaling. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9790765     DOI: 10.1006/geno.1998.5491

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  48 in total

Review 1.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

2.  Inhibitory regulation of Rac activation, membrane ruffling, and cell migration by the G protein-coupled sphingosine-1-phosphate receptor EDG5 but not EDG1 or EDG3.

Authors:  H Okamoto; N Takuwa; T Yokomizo; N Sugimoto; S Sakurada; H Shigematsu; Y Takuwa
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

Review 3.  Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.

Authors:  Victoria A Blaho; Timothy Hla
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

4.  Disorders of tissue transformations of lysophosphatidylcholines at experimental pancreatic diabetes in white rats and peculiarities of the corrective effect of low-energy laser radiation of an extremely low intensity.

Authors:  E B Burlakova; K G Karagezyan; O M Amirkhanyan; S S Ovakimyan; E S Sekoyan
Journal:  Dokl Biochem Biophys       Date:  2010-08-17       Impact factor: 0.788

Review 5.  Insights into the pharmacological relevance of lysophospholipid receptors.

Authors:  Tetsuji Mutoh; Richard Rivera; Jerold Chun
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 6.  An update on the biology of sphingosine 1-phosphate receptors.

Authors:  Victoria A Blaho; Timothy Hla
Journal:  J Lipid Res       Date:  2014-01-23       Impact factor: 5.922

Review 7.  Sphingosine 1-phosphate in coagulation and inflammation.

Authors:  Hideru Obinata; Timothy Hla
Journal:  Semin Immunopathol       Date:  2011-07-31       Impact factor: 9.623

8.  Sphingosine 1-phosphate receptor signaling regulates proper embryonic vascular patterning.

Authors:  Karen Mendelson; Tomasz Zygmunt; Jesús Torres-Vázquez; Todd Evans; Timothy Hla
Journal:  J Biol Chem       Date:  2012-12-10       Impact factor: 5.157

Review 9.  Cardioprotection in ischemia/reperfusion injury: spotlight on sphingosine-1-phosphate and bradykinin signalling.

Authors:  Emmanuel Eroume A Egom; Yunbo Ke; R John Solaro; Ming Lei
Journal:  Prog Biophys Mol Biol       Date:  2010-01-18       Impact factor: 3.667

10.  Pharmacological characterization of human S1P4 using a novel radioligand, [4,5-3H]-dihydrosphingosine-1-phosphate.

Authors:  James Fossetta; Gregory Deno; Waldemar Gonsiorek; Xuedong Fan; Brian Lavey; Pradip Das; Charles Lunn; Paul J Zavodny; Daniel Lundell; R William Hipkin
Journal:  Br J Pharmacol       Date:  2004-06-14       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.